Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
MENLO PARK, Calif., Jan. 22, 2016 -- Pacific Biosciences of California, Inc. (Nasdaq:PACB) is announcing a date change for its conference call to report 4th Quarter and Fiscal Year 2015 financial results. The call with now occur on Wednesday, February 3, at 4:30pm Eastern Time.
The call will be webcast and may be accessed at Pacific Biosciences’ website at: http://investor.pacificbiosciences.com/.
Date: February 3, 2016
Time: 4:30pm ET
Listen via Internet: http://investor.pacificbiosciences.com/
Toll-free: 888.366.7247
International: 707.287.9330
Replay: http://investor.pacificbiosciences.com
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences' products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. Pacific Biosciences' technology provides the industry's highest consensus accuracy over the longest read lengths in combination with the ability to detect real-time kinetic information. PacBio sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
Contact: Pacific Biosciences Trevin Rard 650.521.8450 [email protected]
